Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Myelomonocytic, Acute 1Leukemia, Myeloid, Acute 1Leukemia, Monocytic, Acute 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Erythroblastic, Acute 1Congenital Abnormalities 1

Interventions

Cytarabine 82Etoposide 32Daunorubicin 31Idarubicin 26Filgrastim 26Mitoxantrone 22Busulfan 18Peripheral Blood Stem Cell Transplantation 17fludarabine phosphate 14Gemtuzumab 14Cyclophosphamide 14tipifarnib 11Clofarabine 10Azacitidine 10Radiotherapy 9Methotrexate 9Gene Expression Profiling 9sargramostim 8Flow Cytometry 8Granulocyte Colony-Stimulating Factor 7Decitabine 7Cyclosporine 7alvocidib 6Topotecan 6Tacrolimus 6Bortezomib 6Antilymphocyte Serum 6valspodar 5aldesleukin 5Vorinostat 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia, Myelomonocytic, Acute × Calicheamicins × Clear all
NCT00895934 2019-05-23

Vorinostat, Azacitidine, and Gemtuzumab Ozogamicin for Older Patients With Relapsed or Refractory AML

National Cancer Institute (NCI)

Phase 1/2 Completed
52 enrolled 12 charts
Other hematologic neoplasm

Congenital Abnormalities, Leukemia, Erythroblastic, Acute, Leukemia, Megakaryoblastic, Acute, Leukemia, Monocytic, Acute, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡